Fig. 1: Association between BCL-2 family proteins expression and baseline characteristics, and survival according to BCL-W expression.

A Association between BCL-2A1 levels and previous therapy, and BCL-2 lvels and Th2 phenotype. B BCL-2 immunostain shows strong positivity in only 10% of lymphoma cells (low expression). C BCL-2 immunostain shows strong expression in 100% of lymphoma cells (high expression). D BCL-2A1 immunostain shows negativity in all lymphoma cells (low expression). E BCL-2A1 immunostain shows diffuse and moderate to strong cytoplasmic expression in 80% of lymphoma cells (high expression). F Progression-free survival according to BCL-W expression. G Overall survival according to BCL-W expression. H BCL-W immunostain shows weak cytoplasmic positivity in 40% of lymphoma cells (low expression). I BCL-W immunostain shows diffuse and intense expression in 100% of lymphoma cells (high expression).